Russell Investments Group
ELVN icon

Russell Investments Group’s Enliven Therapeutics ELVN Stock Holding History

Russell Investments Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Sell
3,001
-120
-4% -$3.33K ﹤0.01% 3039
2025
Q4 		$48.1K Sell
3,121
-521
-14% -$10.4K ﹤0.01% 3311
2025
Q3 		$74.6K Sell
3,642
-25,905
-88% -$522K ﹤0.01% 3131
2025
Q2 		$593K Sell
29,547
-75,995
-72% -$1.44M ﹤0.01% 2275
2025
Q1 		$2.08M Buy
105,542
+105,471
+148,551% +$2.27M ﹤0.01% 1674
2024
Q4 		$1.6K Buy
71
+59
+492% +$1.53K ﹤0.01% 3479
2024
Q3 		$306 Sell
12
-1,426
-99% -$33K ﹤0.01% 3611
2024
Q2 		$33.6K Buy
1,438
+1,426
+11,883% +$30K ﹤0.01% 2848
2024
Q1 		$211 Hold
12
– – ﹤0.01% 3275
2023
Q4 		$166 Buy
+12
New +$147 ﹤0.01% 3185
2021
Q3 		– Sell
-48,476
Closed -$1.53M – 3083
2021
Q2 		$1.53M Buy
+48,476
New +$1.5M ﹤0.01% 2079

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Russell Investments Group's ELVN Position: Q1 2026 in Review

Russell Investments Group reduced its Enliven Therapeutics (ELVN) stake by 3.8% in Q1 2026, selling an estimated $3.33K and leaving 3,001 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

Russell Investments Group first reported a position in ELVN in Q2 2021 and has held it in 11 quarters since. The position peaked at $2.08M in Q1 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Russell Investments Group held 3,001 shares of Enliven Therapeutics worth $118K as of Q1 2026.
  • Russell Investments Group sold 120 Enliven Therapeutics shares in Q1 2026, an estimated $3.33K.
  • Enliven Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3039 holding.
  • Russell Investments Group first reported a position in Enliven Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • Russell Investments Group's Enliven Therapeutics position peaked at $2.08M in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.